Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Share-based Compensation (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Share-based Compensation for 7 consecutive years, with $20.4 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 32.33% to $20.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $94.2 million through Dec 2025, down 21.89% year-over-year, with the annual reading at $94.2 million for FY2025, 21.89% down from the prior year.
  • Share-based Compensation for Q4 2025 was $20.4 million at Beam Therapeutics, down from $22.7 million in the prior quarter.
  • The five-year high for Share-based Compensation was $31.6 million in Q2 2024, with the low at $4.6 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $22.1 million, with a median of $22.7 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 330.54% in 2021, then plummeted 32.33% in 2025.
  • Over 5 years, Share-based Compensation stood at $15.5 million in 2021, then skyrocketed by 45.14% to $22.5 million in 2022, then increased by 0.52% to $22.6 million in 2023, then surged by 33.61% to $30.2 million in 2024, then tumbled by 32.33% to $20.4 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $20.4 million, $22.7 million, and $24.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.